Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer

Lung, Respiratory and Thoracic Cancer

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG

doi: 10.1016/j.jtho.2024.09.1437

Lung, Respiratory and Thoracic Cancer

Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial

Lung Cancer

Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L

doi: 10.1016/j.lungcan.2025.108108

Lung, Respiratory and Thoracic Cancer

Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy

Lung Cancer

Yang G, Yoon HI, Lim SM, Hong MH, Cho J, Lee CG, Cho BC, Kim HR, Kim KH

doi: 10.1016/j.lungcan.2025.108574

Lung, Respiratory and Thoracic Cancer

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Lung Cancer

Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L

doi: 10.1016/j.lungcan.2025.108450

Lung, Respiratory and Thoracic Cancer

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial

J Clin Oncol

Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD, Ottosson W, Brink C, Hoffmann L

doi: 10.1200/JCO-24-01386

Lung, Respiratory and Thoracic Cancer

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

Eur J Cancer

Laktionov K, Smolin A, Stroyakovskiy D, Moiseenko V, Dvorkin M, Andabekov T, Cheng Y, Liu B, Kozlov V, Odintsova S, Dvoretsky S, Mochalova A, Urda M, Yi T, Li X, László U, Müller V, Bogos K, Fadeeva N, Musaev G, Liu Q, Kirtbaya D, Shi J, Gladkov O, Narimanov M, Semiglazova T, Khasanova A, Chovanec J, Andrašina I, Szabová A, Rosinská O, Sudekova D, Zsolt PS, Ran F, Sun M, Jiang O, Chen R, Zhao E, Liu C, Tan W, Pirmagomedov A, Poddubskaya E, Kislov N, Shumskaya I, Sorokina I, Zinkina-Orikhan A, Linkova Y, Fogt S, Liaptseva D, Siliutina A, Basova O, Kryukov F

doi: 10.1016/j.ejca.2025.115255

Lung, Respiratory and Thoracic Cancer

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Lung Cancer

Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S

doi: 10.1016/j.lungcan.2025.108496

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Lung Cancer

Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, Gori S, Giannarelli D, Novello S, Passiglia F

doi: 10.1016/j.lungcan.2025.108576

Lung, Respiratory and Thoracic Cancer

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials

Lung Cancer

Auclin E, Roulleaux Dugage M, Gorria T, Vauchier C, Thibault C, Laguna JC, Lupinacci L, Crous C, Naigeon M, Oudard S, Besse B, Mezquita L

doi: 10.1016/j.lungcan.2024.108039

Related content

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial

Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials